A systematic review and meta-analysis of pretherapeutic lymph node staging of colorectal cancer by 18F-FDG PET or PET/CT

Yu Yu Lu, Jin Hua Chen, Hueisch Jy Ding, Chun Ru Chien, Wan Yu Lin, Chia Hung Kao

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

The purpose of the present study was to conduct a systematic review and meta-analysis of the published literature to evaluate the diagnostic performance of fluorine-18 2-fluoro-2-deoxy-D-glucose (F-FDG) PET in the pretherapeutic assessment of nodal staging in patients with colorectal cancer (CRC). We conducted a systematic MEDLINE search of articles in the published literature (last update, February 2012). Two reviewers independently assessed the methodological quality of each study. We estimated pooled sensitivity, specificity, summary receiver operating characteristic curves, and summary likelihood ratios. A total of 409 patients from 10 studies were analyzed. The pooled estimates of sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of F-FDG PET [PET/computed tomography (CT)] in the detection of pretherapeutic lymph node involvement in patients with CRC were 42.9% [95% confidence interval (CI): 36.0-50.0%], 87.9% (95% CI: 82.6-92.0%), 2.82 (95% CI: 1.96-4.07), and 0.69 (95% CI: 0.62-0.78), respectively. There is no solid evidence to support the routine clinical application of F-FDG PET (PET/CT) in the pretherapeutic evaluation of lymph node status in patients with CRC. However, F-FDG PET (PET/CT) could be used to strengthen the possibility of suspected metastatic lymph nodes detected by other imaging modalities.

Original languageEnglish
Pages (from-to)1127-1133
Number of pages7
JournalNuclear Medicine Communications
Volume33
Issue number11
DOIs
Publication statusPublished - Nov 2012
Externally publishedYes

Fingerprint

Fluorine
Fluorodeoxyglucose F18
Meta-Analysis
Colorectal Neoplasms
Lymph Nodes
Tomography
Confidence Intervals
Sensitivity and Specificity
MEDLINE
ROC Curve

Keywords

  • 18F-FDG PET
  • colorectal cancer
  • meta-analysis
  • PET/CT
  • systematic review

ASJC Scopus subject areas

  • Medicine(all)
  • Radiology Nuclear Medicine and imaging

Cite this

A systematic review and meta-analysis of pretherapeutic lymph node staging of colorectal cancer by 18F-FDG PET or PET/CT. / Lu, Yu Yu; Chen, Jin Hua; Ding, Hueisch Jy; Chien, Chun Ru; Lin, Wan Yu; Kao, Chia Hung.

In: Nuclear Medicine Communications, Vol. 33, No. 11, 11.2012, p. 1127-1133.

Research output: Contribution to journalReview article

Lu, Yu Yu ; Chen, Jin Hua ; Ding, Hueisch Jy ; Chien, Chun Ru ; Lin, Wan Yu ; Kao, Chia Hung. / A systematic review and meta-analysis of pretherapeutic lymph node staging of colorectal cancer by 18F-FDG PET or PET/CT. In: Nuclear Medicine Communications. 2012 ; Vol. 33, No. 11. pp. 1127-1133.
@article{011bcedd19104971af2dc7b47ca86155,
title = "A systematic review and meta-analysis of pretherapeutic lymph node staging of colorectal cancer by 18F-FDG PET or PET/CT",
abstract = "The purpose of the present study was to conduct a systematic review and meta-analysis of the published literature to evaluate the diagnostic performance of fluorine-18 2-fluoro-2-deoxy-D-glucose (F-FDG) PET in the pretherapeutic assessment of nodal staging in patients with colorectal cancer (CRC). We conducted a systematic MEDLINE search of articles in the published literature (last update, February 2012). Two reviewers independently assessed the methodological quality of each study. We estimated pooled sensitivity, specificity, summary receiver operating characteristic curves, and summary likelihood ratios. A total of 409 patients from 10 studies were analyzed. The pooled estimates of sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of F-FDG PET [PET/computed tomography (CT)] in the detection of pretherapeutic lymph node involvement in patients with CRC were 42.9{\%} [95{\%} confidence interval (CI): 36.0-50.0{\%}], 87.9{\%} (95{\%} CI: 82.6-92.0{\%}), 2.82 (95{\%} CI: 1.96-4.07), and 0.69 (95{\%} CI: 0.62-0.78), respectively. There is no solid evidence to support the routine clinical application of F-FDG PET (PET/CT) in the pretherapeutic evaluation of lymph node status in patients with CRC. However, F-FDG PET (PET/CT) could be used to strengthen the possibility of suspected metastatic lymph nodes detected by other imaging modalities.",
keywords = "18F-FDG PET, colorectal cancer, meta-analysis, PET/CT, systematic review",
author = "Lu, {Yu Yu} and Chen, {Jin Hua} and Ding, {Hueisch Jy} and Chien, {Chun Ru} and Lin, {Wan Yu} and Kao, {Chia Hung}",
year = "2012",
month = "11",
doi = "10.1097/MNM.0b013e328357b2d9",
language = "English",
volume = "33",
pages = "1127--1133",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - A systematic review and meta-analysis of pretherapeutic lymph node staging of colorectal cancer by 18F-FDG PET or PET/CT

AU - Lu, Yu Yu

AU - Chen, Jin Hua

AU - Ding, Hueisch Jy

AU - Chien, Chun Ru

AU - Lin, Wan Yu

AU - Kao, Chia Hung

PY - 2012/11

Y1 - 2012/11

N2 - The purpose of the present study was to conduct a systematic review and meta-analysis of the published literature to evaluate the diagnostic performance of fluorine-18 2-fluoro-2-deoxy-D-glucose (F-FDG) PET in the pretherapeutic assessment of nodal staging in patients with colorectal cancer (CRC). We conducted a systematic MEDLINE search of articles in the published literature (last update, February 2012). Two reviewers independently assessed the methodological quality of each study. We estimated pooled sensitivity, specificity, summary receiver operating characteristic curves, and summary likelihood ratios. A total of 409 patients from 10 studies were analyzed. The pooled estimates of sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of F-FDG PET [PET/computed tomography (CT)] in the detection of pretherapeutic lymph node involvement in patients with CRC were 42.9% [95% confidence interval (CI): 36.0-50.0%], 87.9% (95% CI: 82.6-92.0%), 2.82 (95% CI: 1.96-4.07), and 0.69 (95% CI: 0.62-0.78), respectively. There is no solid evidence to support the routine clinical application of F-FDG PET (PET/CT) in the pretherapeutic evaluation of lymph node status in patients with CRC. However, F-FDG PET (PET/CT) could be used to strengthen the possibility of suspected metastatic lymph nodes detected by other imaging modalities.

AB - The purpose of the present study was to conduct a systematic review and meta-analysis of the published literature to evaluate the diagnostic performance of fluorine-18 2-fluoro-2-deoxy-D-glucose (F-FDG) PET in the pretherapeutic assessment of nodal staging in patients with colorectal cancer (CRC). We conducted a systematic MEDLINE search of articles in the published literature (last update, February 2012). Two reviewers independently assessed the methodological quality of each study. We estimated pooled sensitivity, specificity, summary receiver operating characteristic curves, and summary likelihood ratios. A total of 409 patients from 10 studies were analyzed. The pooled estimates of sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of F-FDG PET [PET/computed tomography (CT)] in the detection of pretherapeutic lymph node involvement in patients with CRC were 42.9% [95% confidence interval (CI): 36.0-50.0%], 87.9% (95% CI: 82.6-92.0%), 2.82 (95% CI: 1.96-4.07), and 0.69 (95% CI: 0.62-0.78), respectively. There is no solid evidence to support the routine clinical application of F-FDG PET (PET/CT) in the pretherapeutic evaluation of lymph node status in patients with CRC. However, F-FDG PET (PET/CT) could be used to strengthen the possibility of suspected metastatic lymph nodes detected by other imaging modalities.

KW - 18F-FDG PET

KW - colorectal cancer

KW - meta-analysis

KW - PET/CT

KW - systematic review

UR - http://www.scopus.com/inward/record.url?scp=84866847903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866847903&partnerID=8YFLogxK

U2 - 10.1097/MNM.0b013e328357b2d9

DO - 10.1097/MNM.0b013e328357b2d9

M3 - Review article

C2 - 23000829

AN - SCOPUS:84866847903

VL - 33

SP - 1127

EP - 1133

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 11

ER -